U.S. Minimal Residual Disease Testing Market (2025 - 2033) Size, Share & Trends Analysis Report By Technology (Flow Cytometry, PCR, NGS), By Cancer Type (Hematological Malignancy, Solid Tumors), By End Use, And Segment Forecasts
- Report Summary
- Table of Contents
- Segmentation
- Methodology
- Download FREE Sample
-
Download Sample Report
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Technology Segment
1.1.1.2. Cancer Type Segment
1.1.1.3. End Use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Primary Sources
1.11. List of Abbreviations
Chapter 2. U.S. Minimal Residual Disease Testing Market: Executive Summary
2.1. Market Snapshot
2.2. Technology and Services Snapshots
2.3. Cancer Type and End Use Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. U.S. Minimal Residual Disease Testing Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Rising incidence and prevalence of hematological malignancies
3.4.2. Technological advancements in diagnostic tools
3.4.3. Integration with personalized medicines
3.5. Market Restraint Analysis
3.5.1. High cost and limited accessibility of advanced MRD technologies
3.6. U.S. Minimal Residual Disease Testing Market Analysis Tools
3.6.1. Industry Analysis - Porter’s
3.6.1.1. Supplier Power
3.6.1.2. Buyer Power
3.6.1.3. Substitution Threat
3.6.1.4. Threat of New Entrants
3.6.1.5. Competitive Rivalry
3.6.2. PESTLE Analysis
3.6.2.1. Political Landscape
3.6.2.2. Technological Landscape
3.6.2.3. Economic Landscape
Chapter 4. U.S. Minimal Residual Disease Testing: Products, Estimates & Trend Analysis
4.1. Product Market Share, 2024 & 2033
4.2. Segment Dashboard
4.3. U.S. Minimal Residual Disease Testing Market, By Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2021 To 2033 For The Following
4.4.1. Flow Cytometry
4.4.1.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
4.4.2. Polymerase Chain Reaction (PCR)
4.4.2.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
4.4.3. Next Generation Sequencing (NGS)
4.4.3.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
4.4.3.2. Amplicon-based NGS
4.4.3.2.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
4.4.3.3. Hybridization Capture-based NGS
4.4.3.3.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
4.4.3.4. Others
4.4.3.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
4.4.4. Others
4.4.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
Chapter 5. U.S. Minimal Residual Disease Testing: Cancer Type Estimates & Trend Analysis
5.1. Cancer Type Market Share, 2024 & 2033
5.2. Segment Dashboard
5.3. U.S. Minimal Residual Disease Testing Market, By Cancer Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2021 To 2033 For The Following
5.4.1. Hematological Malignancy
5.4.1.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.1.2. Leukemia
5.4.1.2.1. Market Estimates and Forecasts 2021 To 2033 (USD Million)
5.4.1.3. Lymphoma
5.4.1.3.1. Market Estimates and Forecasts 2021 To 2033 (USD Million)
5.4.2. Solid Tumors
5.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Minimal Residual Disease Testing: End Use Estimates & Trend Analysis
6.1. End Use Market Share, 2024 & 2033
6.2. Segment Dashboard
6.3. Global U.S. Minimal Residual Disease Testing Market, By End Use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2021 To 2033 For The Following
6.4.1. Hospitals and Specialty Clinics
6.4.1.1. Market Estimates and Forecasts 2021 To 2033 (USD Million)
6.4.2. Diagnostic Laboratories
6.4.2.1. Market Estimates and Forecasts 2021 To 2033 (USD Million)
6.4.3. Academic and Research Institutes
6.4.4. Others
6.4.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company /Competition Categorization
7.3. Vendor Landscape
7.3.1. List of Key Distributors and Channel Partners
7.3.2. Key Customers
7.3.3. Key Company Market Share Analysis, 2024
7.3.4. Twist Bioscience
7.3.4.1. Overview
7.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.4.3. Product Benchmarking
7.3.4.4. Strategic Initiatives
7.3.5. Thermo Fisher Scientific, Inc
7.3.5.1. Overview
7.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.5.3. Product Benchmarking
7.3.5.4. Strategic Initiatives
7.3.6. Illumina, Inc.
7.3.6.1. Overview
7.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.6.3. Product Benchmarking
7.3.6.4. Strategic Initiatives
7.3.7. QIAGEN
7.3.7.1. Overview
7.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.7.3. Product Benchmarking
7.3.7.4. Strategic Initiatives
7.3.8. Adaptive Biotechnologies
7.3.8.1. Overview
7.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.8.3. Product Benchmarking
7.3.8.4. Strategic Initiatives
7.3.9. Natera, Inc.
7.3.9.1. Overview
7.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.9.3. Product Benchmarking
7.3.9.4. Strategic Initiatives
7.3.10. Guardant Health
7.3.10.1. Overview
7.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.10.3. Product Benchmarking
7.3.10.4. Strategic Initiatives
7.3.11. Foresight Diagnostics, Inc.
7.3.11.1. Overview
7.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.11.3. Product Benchmarking
7.3.11.4. Strategic Initiatives
7.3.12. NeoGenomics, Inc.
7.3.12.1. Overview
7.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.12.3. Product Benchmarking
7.3.12.4. Strategic Initiatives
7.3.13. . Hoffmann-La Roche Ltd.
7.3.13.1. Overview
7.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.13.3. Product Benchmarking
7.3.13.4. Strategic Initiatives
7.3.14. SOPHiA GENETICS
7.3.14.1. Overview
7.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.3.14.3. Product Benchmarking
7.3.14.4. Strategic Initiatives
List of Tables
Table 1. List of key distributors and channel partners
Table 2. List of key emerging companies’/technology disruptors/innovators
Table 3. U.S. Minimal Residual Disease Testing Market, By Product, 2021 - 2033 (USD Million)
Table 4. U.S. Minimal Residual Disease Testing Market, By Cancer Type, 2021 - 2033 (USD Million)
Table 5. U.S. Minimal Residual Disease Testing Market, By End Use, 2021 - 2033 (USD Million)
LIst of Figures
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 U.S. Minimal Residual Disease Testing Market Segmentation
Fig. 8 Market Snapshot, 2024
Fig. 9 Market Trends & Outlook
Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
Fig. 14 Porter’s Five Forces Analysis
Fig. 15 Market Penetration Vs Growth Prospect Mapping, 2024
Fig. 16 U.S. Minimal Residual Disease Testing Market: Product Movement Analysis
Fig. 17 U.S. Minimal Residual Disease Testing Market: Product Outlook and Key Takeaways
Fig. 18 Flow Cytometry
Fig. 19 Polymerase Chain Reaction (PCR)
Fig. 20 Next Generation Sequencing (NGS)
Fig. 21 Others Market Estimates and Forecast, 2021 - 2033
Fig. 22 Amplicon-based NGS Market Estimates and Forecast, 2021 - 2033
Fig. 23 Hybridization Capture-based NGS Market Estimates and Forecast, 2021 - 2033
Fig. 24 Other Estimates and Forecast, 2021 - 2033
Fig. 25 U.S. Minimal Residual Disease Testing Market: Cancer Type Movement Analysis
Fig. 26 U.S. Minimal Residual Disease Testing Market: Cancer Type Outlook and Key Takeaways
Fig. 27 Hematological Malignancy Market Estimates and Forecasts, 2021 - 2033
Fig. 28 Solid Tumors Market Estimates and Forecasts, 2021 - 2033
Fig. 29 Blood & Blood-based Products Market Estimates and Forecasts,2021 - 2033
Fig. 30 Leukemia Market Estimates and Forecasts,2021 - 2033
Fig. 31 Lymphoma Market Estimates and Forecasts,2021 - 2033
Fig. 32 U.S. Minimal Residual Disease Testing Market: End Use Movement Analysis
Fig. 33 U.S. Minimal Residual Disease Testing Market: End Use Outlook and Key Takeaways
Fig. 34 Hospitals and Specialty Clinics Market Estimates and Forecasts, 2021 - 2033
Fig. 35 Diagnostic Laboratories Market Estimates and Forecasts, 2021 - 2033
Fig. 36 Academic and Research Institutes Market Estimates and Forecasts, 2021 - 2033
Fig. 37 Others Market Estimates and Forecasts, 2021 - 2033
Get Free Sample Report
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
Trusted market insights - try a free sample
See how our reports are structured and why industry leaders rely on Grand View Research. Get a free sample or ask us to tailor this report to your needs.
